Ignite Creation Date:
2025-12-25 @ 2:09 AM
Ignite Modification Date:
2025-12-26 @ 12:36 AM
Study NCT ID:
NCT07164560
Status:
RECRUITING
Last Update Posted:
2025-09-10
First Post:
2025-09-02
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Exploratory Study of TRBC1/2-Targeted CAR-T Cell Therapy in Relapsed/Refractory Peripheral T-Cell Lymphoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016411', 'term': 'Lymphoma, T-Cell, Peripheral'}, {'id': 'D012008', 'term': 'Recurrence'}], 'ancestors': [{'id': 'D016399', 'term': 'Lymphoma, T-Cell'}, {'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 45}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-09-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-08', 'completionDateStruct': {'date': '2028-09-01', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-02', 'studyFirstSubmitDate': '2025-09-02', 'studyFirstSubmitQcDate': '2025-09-02', 'lastUpdatePostDateStruct': {'date': '2025-09-10', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-09-10', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-09-01', 'type': 'ESTIMATED'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'Overall response rate (ORR)', 'timeFrame': '3 months', 'description': 'To determine the anti-tumor effectivity of PB TRBC1/2 CAR-T'}, {'measure': 'Progression free survival (PFS)', 'timeFrame': 'Up to 2 years', 'description': 'To determine the anti-tumor effectivity of PB TRBC1/2 CAR-T'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Up to 2 years', 'description': 'To determine the anti-tumor effectivity of PB TRBC1/2 CAR-T'}, {'measure': 'Duration of response (DOR)', 'timeFrame': 'Up to 2 years', 'description': 'To determine the anti-tumor effectivity of PB TRBC1/2 CAR-T'}], 'primaryOutcomes': [{'measure': 'Incidence of dose limiting toxicity (DLTs)', 'timeFrame': 'Up to 28 days', 'description': 'To evaluate the safety, tolerability, and determine the recommended dosage of peripheral blood-derived Anti-TRBC1/2 CAR-T Cell Therapy for refractory/relapsed peripheral T-cell lymphoma.'}], 'secondaryOutcomes': [{'measure': 'Complete response rate (CR)', 'timeFrame': '3 months', 'description': 'To determine the anti-tumor effectivity of PB TRBC1/2 CAR-T'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Refractory/recurrent', 'TRBC1/2 CAR-T', 'Peripheral T-cell lymphoma'], 'conditions': ['Refractory/Recurrent Peripheral T-cell Lymphoma']}, 'descriptionModule': {'briefSummary': 'This study aims to evaluate the safety and efficacy of TRBC1/2-directed chimeric antigen receptor T cells (TRBC1/2 CAR-T cells) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL).', 'detailedDescription': 'This is a multicenter, open-label, single-arm, phase I clinical trial designed to evaluate the safety and efficacy of TRBC1/2 CAR-T cell therapy in patients with TRBC1/2-positive T-cell lymphoma.\n\nThe study will be conducted in two parts:\n\nPhase I (Dose Escalation):\n\nA dose-escalation study will be carried out following the conventional "3+3" design, with one dose level administered via intravenous infusion. Each cohort will enroll 3 to 6 patients. After the initial infusion, patients will be observed for at least 28 days for safety evaluation, followed by long-term follow-up of up to 2 years post-infusion.\n\nPhase II (Dose Expansion):\n\nBased on safety, in vivo expansion and persistence of TRBC1/2 CAR-T cells, and preliminary efficacy results from Phase I, the recommended dose and administration schedule will be determined. Approximately 30 eligible patients will then be enrolled to further assess safety and efficacy at the selected dose. Following the first infusion of TRBC1/2 CAR-T cells, patients will continue in long-term follow-up for up to 2 years.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria\n\nAccording to the 2016 WHO classification of lymphoid neoplasms, patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) must meet the following criteria to be eligible for enrollment:\n\n1. Voluntarily agree to participate in this study and provide signed informed consent.\n2. Age 18 to 75 years, male or female.\n3. Diagnosis of relapsed/refractory PTCL, defined as failure of ≥1 prior line of therapy. Eligible histologic subtypes include (but are not limited to):\n\n Angioimmunoblastic T-cell lymphoma (AITL) Anaplastic large cell lymphoma (ALCL) Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS)\n4. Estimated life expectancy ≥12 weeks.\n5. TRBC1/2-positive tumor tissue (≥20% by immunohistochemistry) OR TCR gene rearrangement confirmed by PCR or NGS.\n6. ECOG performance status of 0-2.\n7. Adequate organ function as defined below:\n\n ALT and AST ≤ 2.5 × upper limit of normal (ULN) Creatinine clearance (Cockcroft-Gault) ≥ 60 mL/min Total bilirubin ≤ 1.5 × ULN Left ventricular ejection fraction (LVEF) ≥ 50% Baseline oxygen saturation \\> 92% on room air\n\n Hematology:\n\n Phase Ia: ANC \\> 1500/mm³, platelets \\> 75 × 10⁹/L, hemoglobin \\> 9 g/dL Phase Ib: ANC \\> 1000/mm³, platelets \\> 50 × 10⁹/L, hemoglobin \\> 8 g/dL\n8. ≥3 months since prior autologous hematopoietic stem cell transplantation.\n9. Prior CAR-T therapy targeting a different antigen is permitted if lack of efficacy was confirmed after ≥3 months of evaluation, or if complete remission (CR) was achieved but relapse occurred.\n10. Women of childbearing potential must have a negative pregnancy test prior to enrollment. All patients (male and female) must agree to use effective contraception during the study.\n11. Presence of at least one measurable lesion.\n12. All approved prior anti-tumor therapies (including systemic chemotherapy, total body irradiation, or immunotherapy) must have been completed ≥3 weeks before study drug administration; for non-chemotherapy targeted agents, a washout period of ≥2 weeks is required.\n\nExclusion Criteria\n\nPatients meeting any of the following criteria will be excluded from this study:\n\n1. History of allergy to any component of the cell product.\n2. History of another malignancy that has not achieved remission.\n3. Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation.\n4. Receipt of gene therapy within the past 3 months.\n5. Uncontrolled systemic active infection (with the exception of simple urinary tract infection or bacterial pharyngitis). Prophylactic use of antibiotics, antivirals, or antifungal agents is permitted.\n6. Active hepatitis B infection (HBsAg positive; however, patients with HBV-DNA \\<10³ copies/mL are not excluded), active hepatitis C virus infection (including carriers), syphilis, or other acquired or congenital immunodeficiency diseases, including but not limited to HIV infection.\n7. New York Heart Association (NYHA) Class III or IV heart failure.\n8. Unresolved toxicity from prior anti-tumor therapy (defined as CTCAE v5.0 Grade \\>1, with the exception of fatigue, anorexia, and alopecia).\n9. Evidence of central nervous system (CNS) involvement at screening, or clinically significant CNS disease such as a history of seizures or other CNS disorders.\n10. Prior exposure to any agent specifically targeting TRBC1/2.\n11. Lactating women who are unwilling to discontinue breastfeeding.\n12. Any other condition that, in the opinion of the investigator, may increase patient risk or interfere with the study results.\n13. Autoimmune disease requiring immunosuppressive therapy.\n14. Use of immunosuppressive agents or therapeutic doses of corticosteroids (defined as prednisone \\>20 mg/day or equivalent) within 7 days prior to leukapheresis, or use of hematopoietic growth factors such as G-CSF. Physiological replacement therapy, topical, or inhaled corticosteroids are permitted.\n15. Receipt of chemotherapy, targeted therapy, immunotherapy, or radiotherapy within 3 days prior to leukapheresis.\n16. Participation in another clinical trial within 4 weeks or within 5 half-lives of the investigational product (whichever is shorter) prior to leukapheresis.'}, 'identificationModule': {'nctId': 'NCT07164560', 'briefTitle': 'Exploratory Study of TRBC1/2-Targeted CAR-T Cell Therapy in Relapsed/Refractory Peripheral T-Cell Lymphoma', 'organization': {'class': 'OTHER', 'fullName': 'Second Affiliated Hospital, School of Medicine, Zhejiang University'}, 'officialTitle': 'Clinical Study of TRBC1/2-Targeted CAR-T Cells in the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma', 'orgStudyIdInfo': {'id': '2025-0638'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'PB TRBC1/2 CAR-T', 'interventionNames': ['Biological: Anti-TRBC1 CAR-T cells']}], 'interventions': [{'name': 'Anti-TRBC1 CAR-T cells', 'type': 'BIOLOGICAL', 'description': 'lentiviral vector-transducted peripheral blood-derived T cells to express anti-TRBC1 CAR', 'armGroupLabels': ['PB TRBC1/2 CAR-T']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Hangzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Wenbin Qian', 'role': 'CONTACT', 'email': 'qianwb@zju.edu.cn', 'phone': '+87-57189713672'}], 'facility': '2nd Affiliated Hospital,School of Medicine,Zhejiang University', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}], 'centralContacts': [{'name': 'Wenbin Qian, professor', 'role': 'CONTACT', 'email': 'Qianwb@zju.edu.cn', 'phone': '87-57189713672'}, {'name': 'Xinbin Xiao, Doctor', 'role': 'CONTACT', 'email': 'xiaoxibinzju@zju.edu.cn', 'phone': '13858015535'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Second Affiliated Hospital, School of Medicine, Zhejiang University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Peking University Cancer Hospital & Institute', 'class': 'OTHER'}, {'name': 'Ruijin Hospital', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}